OncLive TV

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Christopher Pleyer, MD, discusses the next steps with ​the combination of ibrutinib and ​short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Nicole Concin, MD, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.